reported that an elevated level of METTL3 could potentiate resistance to cisplatin through the m6A modification of transcription factor‐activating enhancer‐binding protein 2C in seminoma, indicating the oncogenic role of high levels of METTL3. Here, METTL3 is linked to seminoma.